Masimo Demonstrates Advanced Health Tracking Watch Integrated with Philips’s Enterprise Patient Monitoring Ecosystem

By HospiMedica International staff writers
Posted on 31 Jan 2023

Image: Masimo W1 and Philips Enterprise Patient Monitoring (Photo courtesy of Masimo)

Masimo (Irvine, CA, USA) and Philips Healthcare (Amsterdam‎, Noord-Holland) are showcasing the Masimo W1 advanced health tracking watch, their combined innovation that draws upon their extensive expertise in monitoring, connectivity, and automation, at Arab Health 2023.

Masimo and Philips recently expanded their partnership to augment patient monitoring capabilities in home telehealth applications with the Masimo W1. The W1 will integrate with Philips’s enterprise patient monitoring ecosystem to advance the forefront of telemonitoring and telehealth. The Masimo W1 being showcased at Arab Health 2023 is the first watch to offer accurate, continuous pulse oximetry measurements and other insightful health data. Using Masimo’s secure health data cloud, patient information will be relayed to the Philips patient monitoring ecosystem for remote clinician surveillance.

Hospital clinicians will be able to seamlessly and remotely monitor key health markers as their patients move throughout their homes and go about their daily lives. Physicians will be able to more confidently discharge patients knowing that their vital signs will still be monitored (via Masimo W1) and their physiological status tracked (via Philips dashboards), helping them catch possible patient deterioration sooner and make more informed interventions. This breakthrough combination of monitoring and connectivity technologies will enable numerous opportunities supporting early discharge initiatives, hospital-at-home programs, and chronic illness management. Masimo W1 for use in medical applications is CE marked and is pending FDA clearance.

“Expanding our partnership with Philips in this way is a win-win for patients and clinicians everywhere, and is an important part of our multi-year plan to bring the best of hospital monitoring to the home while continuing to improve access to quality hospital care,” said Bilal Muhsin, Chief Operating Officer of Masimo Healthcare.

“At Philips, we believe in an open ecosystem of information that enables physicians in their daily routine, allows for them to access and process vital patient information and deploy a wide range of measurements and patient-worn technologies,” added Christoph Pedain, General Manager, Hospital Patient Monitoring at Philips. “Our integration of the latest Masimo technologies is a testament to that strategy and we are delighted to deepen our relationship with Masimo.”

Related Links:
Masimo
Philips Healthcare

Visit expo >

New

Gold Member

Handheld Blood Glucose Analyzer

STAT-Site

Antipsychotic TDM Assays
Saladax Antipsychotic Assays

New

Blood Gas Analyzer

i-Check200

New

Hypodermic Syringe

SurTract™ Safety Syringe

Latest ARAB HEALTH 2023 News

Channels

Artificial Intelligence

view channel

Machine Learning Approach Enhances Liver Cancer Risk Stratification

Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read more

Image: connected devices offer new possibilities in the early detection of abnormalities or changes in brain health (Photo courtesy of 123RF)

New AI Approach Monitors Brain Health Using Passive Wearable Data

Brain health spans cognitive and emotional functions and can fluctuate even in adults without diagnosed disease. Detecting early changes remains difficult in routine care and burdens specialty services... Read more

$Image: Study procedure flow chart. After patients with BSI were identified from microbiology databases, 27 patients\' characteristics were extracted from electronic health records. After the dimension of those variables was reduced with Uniform Manifold Approximation and Projection (UMAP), k-means++ was used to identify clusters. Three clinically distinct clusters were identified. Among those clusters, patients were divided into solid organ transplant (SOT) and non-SOT groups. Clinical characteristics and outcomes were evaluated (Masayuki Nigo et al., American Journal of Transplantation (2026). DOI: 10.1016/j.ajt.2025.10.019)$